Our results show that the drugs most commonly suspected to cause PRES were antineoplastics, immunosuppressants, and glucocorticoids. Future studies are needed to illuminate the pathophysiological alterations that underlie PRES. In the meantime, prescribers and patients should be made aware of the potential risks of PRES associated with pharmaceutical therapy, and the summaries of product characteristics for individual drugs should be updated to include this information.
Keyphrases
- adverse drug
- drug induced
- liver injury
- end stage renal disease
- human health
- drug administration
- electronic health record
- ejection fraction
- chronic kidney disease
- newly diagnosed
- emergency department
- peritoneal dialysis
- risk assessment
- case report
- pulmonary embolism
- health information
- healthcare
- current status
- patient reported outcomes
- climate change
- case control
- patient reported